Ludocare, a Lyon-based digital therapy startup, has secured €4.2M from Karista and Bpifrance, participating via its Patient Autonome fund and the French Tech Seed fund. The funding will enable the launch of a clinical study, implement medical prescription strategy, and strengthen its teams.
Around 10.7% of children suffer from asthma in France, representing a public health issue with compliance estimated at barely 30% due to the cumbersome nature of the treatments and the complexity of the proper use of devices. The overall cost of poor compliance with chronic diseases reaches nearly €9.4B in France.
Improve children with chronic diseases
Founded in 2017, Ludocare is on a mission to improve the health of children with chronic diseases through dedicated solutions. The company has developed a connected medical companion dedicated to children suffering from chronic diseases such as asthma.
Ludocare’s robot rings and calls the child and accompanies him step by step by stating the name of the medicines and their dosage as well as showing the right gestures to make through animations on the screen.
It motivates the child by unlocking daily multimedia rewards. The robot also transmits data on treatments taken to parents via the connected application.
Alexandra de la Fontaine, Ludocare’s president, and founder says, “Beyond the medical impact, chronic disease is discriminant. Our commitment and motivation at Ludocare are more than ever to respond to this major public health issue that has not been addressed for so many years. We contribute to the improvement of the physical and psychological health of children and to the expected mental relief of their families. This fundraising will allow us to demonstrate the clinical and economic benefits of our digital therapy. Our strategy is to make France a springboard for international expansion.”
Catherine Boule, GM of Karista says, “Ludocare has a resolutely original and innovative approach, attempting to get to the root of the problem, i.e., from a very young age. The first results obtained with the robot in over 200 families are very encouraging and show a drastic improvement in compliance over time. These results must now be validated clinically. Ludocare’s strength also lies in its platform, which can be adapted to several chronic diseases. We are delighted to support Ludocare and its team in this important new phase, which should open the door to reimbursement in France before entering other geographies.”
Joséphine Marie, an investor at Bpifrance, says, “We were attracted by Ludocare’s unique positioning, which addresses major public health and social problem: the lack of compliance among children suffering from chronic diseases, starting with asthma, the leading chronic pediatric disease whose management can be significantly improved. The potential to create a platform that is extended to other diseases and other countries seems to us to create value over time.”